The V600E BRAF mutation in a borderline serous tumour of the testis is genotypic evidence of similarity with its phenotypic ovarian counterpart

Ovarian-type Tumors (Mullerian Tumors) of the Testis: Clinicopathologic Findings with Recent Advances

“…Recent studies on ovarian-type testicular tumors have focused on molecular characterization and the role of adjuvant therapy in treatment, particularly for serous tumors. In the past few years, several studies demonstrated the presence of the BRAF V600E mutation in SBTs of the testis, also seen in SBTs and lowgrade serous carcinomas of the ovary [18,28,107]. This finding provides a clear genetic association between testicular and ovarian low-grade serous neoplasms and suggests similar pathogenesis to ovarian SBTs and low-grade serous carcinomas believed to derive from Mullerian metaplasia of surface epithelium [28].…”

“…In the past few years, several studies demonstrated the presence of the BRAF V600E mutation in SBTs of the testis, also seen in SBTs and lowgrade serous carcinomas of the ovary [18,28,107]. This finding provides a clear genetic association between testicular and ovarian low-grade serous neoplasms and suggests similar pathogenesis to ovarian SBTs and low-grade serous carcinomas believed to derive from Mullerian metaplasia of surface epithelium [28]. However, while the BRAF V600E mutation has been shown in testicular SBTs, it has not been extensively studied for testicular serous carcinomas.…”

“…However, while the BRAF V600E mutation has been shown in testicular SBTs, it has not been extensively studied for testicular serous carcinomas. It is possible that the BRAF V600E mutation may be present in low-grade serous carcinomas, but not highgrade tumors,as their ovarian counterparts have a completely different proposed histogenesis (from fallopian tube epithelium) and molecular alterations (TP53 mutations) [28,107]. In fact, an extensive literature review showed that stratification of testicular serous carcinomas into low-and high-grade tumors is not an established practice as it is for ovarian serous carcinomas [28,107].…”

“…It is possible that the BRAF V600E mutation may be present in low-grade serous carcinomas, but not highgrade tumors,as their ovarian counterparts have a completely different proposed histogenesis (from fallopian tube epithelium) and molecular alterations (TP53 mutations) [28,107]. In fact, an extensive literature review showed that stratification of testicular serous carcinomas into low-and high-grade tumors is not an established practice as it is for ovarian serous carcinomas [28,107]. Given the vastly different origins of these tumors and the aforementioned suggestion that low-grade serous carcinomas may constitute a much higher proportion of serous cancers in the testis compared to the ovary, further molecular analysis of testicular serous carcinomas is warranted.…”

The mutational frequency of BRAF and KRAS in low‐grade serous testicular neoplasms—a case series

“…Non‐germ cell origin epithelial neoplasms are extremely infrequent in the testis: the rare cases reported in testicular and paratesticular tissues include mucinous, endometrioid, clear cell and transitional (Brenner) cell neoplasms and serous neoplasms . Among these, testicular neoplasms showing ovarian serous epithelial‐type morphology are the most common, although only a handful of case reports or case series have been published . Consequently, little is known about the histogenesis and molecular aberrations that result in these neoplasms, but there are striking morpho‐phenotypic similarities between these testicular neoplasms and their ovarian counterparts .…”